Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Frontiers in Neurology is a premier open-access journal dedicated to the advancement of research in the field of neurology, published by FRONTIERS MEDIA SA since 2010. With the ISSN 1664-2295 and an international reach established from its base in Lausanne, Switzerland, this journal has rapidly become a vital resource for neurologists and neuroscientists alike, presenting high-quality research that addresses critical developments in clinical and experimental neurology. Holding a solid Q2 quartile ranking in both neurology and clinical neurology, Frontiers in Neurology demonstrates substantial influence, evidenced by its respectable Scopus rankings—151st in clinical neurology and 77th in neuroscience neurology. The journal employs robust peer review practices to ensure rigor and integrity, while its open-access model fosters widespread dissemination of knowledge. By facilitating interdisciplinary dialogue and empowering research efforts, this journal not only supports the academic community but also contributes to the advancement of treatment and understanding of neurological disorders.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Neurology International is a prestigious open-access journal published by MDPI that has been making significant contributions to the field of neurology since its establishment in 2009. With its ISSN 2035-8377, this journal is committed to disseminating high-quality, peer-reviewed research that addresses a wide range of clinical topics in neurology. Operating out of Basel, Switzerland, the journal holds a respectable Q2 ranking in the clinical neurology category as of 2023, indicating its influence and dedication to advancing scientific knowledge. Researchers and practitioners alike will find value in its comprehensive articles, which are readily accessible to a global audience, facilitating the sharing of innovative findings and clinical practices. As it converges towards 2024, Neurology International continues to provide a vital platform for scholarly discourse, aiming to improve patient outcomes and enhance our understanding of neurological disorders.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

INFLAMMOPHARMACOLOGY is a premier journal published by SPRINGER BASEL AG, specializing in the evolving fields of immunology and pharmacology. Established in 1991, the journal has made significant strides in contributing to the understanding of inflammation-related disorders, therapeutic innovations, and the pharmacological implications associated with these conditions. With an impressive Q2 ranking in Immunology and Q1 rankings in both Pharmacology and Medical Pharmacology for 2023, alongside notable Scopus rankings, INFLAMMOPHARMACOLOGY maintains its position at the forefront of scientific research. The journal provides a vital platform for researchers and practitioners to disseminate groundbreaking findings and explore novel approaches in therapeutics, reinforcing the importance of evidence-based medicine. Accessible exclusively through traditional subscription options, it continues to attract a diverse readership invested in advancing knowledge within these cutting-edge disciplines.

Annals of Clinical and Translational Neurology is a premier journal published by WILEY, focusing on the fields of neurology and neuroscience. Since its inception in 2014, it has established itself as an Open Access platform, providing unrestricted access to cutting-edge research to promote scientific collaboration and innovation. With an impressive Impact Factor residing in the top quartile (Q1) for both clinical neurology and miscellaneous neuroscience in 2023, this journal ranks #52 out of 400 in the Neurology category and #22 out of 113 in General Neuroscience, indicating its significant contribution to the field. The journal welcomes submissions that address emerging trends and challenges in translational neurology, aiming to bridge the gap between laboratory research and clinical practice. By disseminating high-quality research and fostering a community of scholars, Annals of Clinical and Translational Neurology plays a vital role in advancing our understanding of neurological disorders and improving patient care worldwide.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.